F-10: Cardiol Therapeutics Amends Shelf for $150M Offering

Cardiol Therapeutics Inc. amended its shelf prospectus for a potential US$150 million securities offering, highlighting positive clinical data for CardiolRx in recurrent pericarditis and FDA Orphan Drug Designation.

Summary

• Cardiol Therapeutics Inc. filed an Amendment No. 1 dated October 30, 2025, to its Short Form Base Shelf Prospectus dated July 12, 2024, with the SEC on November 5, 2025.
• The amendment allows for the offering and issuance of Common Shares, Debt Securities, Warrants, Subscription Receipts, and Units up to an aggregate initial offering price of US$150,000,000.
• The amended prospectus also includes provisions for secondary offerings by various selling securityholders.
• The company announced positive 8-week clinical data from its Phase II open-label MAvERIC-Pilot study for recurrent pericarditis, showing a mean reduction of 3.7 in patient-reported pericardial pain (from 5.8 at baseline to 2.1) on an 11-point numerical rating scale.
• Normalization of inflammation, as measured by C-reactive protein (CRP), was observed in 80% of patients with elevated CRP at baseline in the MAvERIC-Pilot study, with mean CRP decreasing from 5.7 mg/dL to 0.3 mg/dL.
• 89% of MAvERIC-Pilot study patients (24 out of 27) progressed from the 8-week treatment period into the 18-week extension period.
• The ARCHER trial, a Phase II multi-national trial for acute myocarditis, has exceeded 85% of its patient enrollment objective.
• CardiolRx received FDA Orphan Drug Designation for the treatment of pericarditis, including recurrent pericarditis, on February 15, 2024.
• As of March 31, 2024, the company reported cash and cash equivalents of $28,572,975 and a total capitalization of $20,059,172, with an accumulated deficit of $(151,756,434).
• The company was classified as a Passive Foreign Investment Company (PFIC) for the taxable year ended December 31, 2023, and expects to be a PFIC for the current taxable year, which may have adverse U.S. federal income tax consequences for U.S. investors.

Sentiment

Score: 7

Explanation: The filing presents strong positive clinical data for CardiolRx in recurrent pericarditis and a significant regulatory achievement with FDA Orphan Drug Designation. The shelf prospectus provides substantial financial flexibility for future development. However, the company's history of losses, negative cash flow, and the inherent high risks and costs of drug development, coupled with the PFIC status for U.S. investors, temper the overall positive sentiment.

Positives

• FDA Orphan Drug Designation for CardiolRx in pericarditis provides significant incentives, including seven-year marketing exclusivity and exemptions from certain FDA fees, and potential for accelerated regulatory review.
• Positive 8-week clinical data from the MAvERIC-Pilot study demonstrated a substantial reduction in patient-reported pericardial pain (mean 3.7 reduction) and normalization of inflammation (80% CRP normalization).
• High patient retention (89%) in the MAvERIC-Pilot study, with 24 out of 27 patients progressing to the extension period, suggests good tolerability and potential efficacy.
• The ARCHER trial for acute myocarditis has exceeded 85% patient enrollment, indicating good progress in its Phase II study.
• The shelf prospectus allows for significant financial flexibility, enabling the company to raise up to US$150 million through various securities to fund ongoing operations and development.

Negatives

• The company has a history of losses and negative cash flow from operations, including for the year ended December 31, 2023.
• A substantial accumulated deficit of $(151,756,434) as of March 31, 2024, indicates ongoing financial challenges.
• The company's classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes for 2023 and expected for the current year could lead to significant adverse tax consequences for U.S. investors.
• Reliance on early-stage product candidates means there is no current revenue generation from product sales, and future success is uncertain.
• The inherent uncertainty, high cost, and potential for delays or negative results in clinical trials pose significant risks to the company's future prospects.

Risks

• Inherent uncertainty of product development, including testing, research, preclinical studies, and clinical trials.
• Requirement for additional financing due to negative cash flow from operations and history of losses.
• Dependence on the success of early-stage product candidates which may not generate revenue, if approved.
• Reliance on management, potential loss of key personnel, or inability to attract new management team members.
• Ability to successfully design, initiate, execute, and complete clinical trials, including high cost, uncertainty, and delay.
• Uncertainty that investigational products will have a therapeutic benefit in the clinical indications being pursued.
• Potential equivocal or negative results from clinical trials and their adverse impacts on future commercialization efforts.
• Ability to receive and maintain regulatory exclusivities in multiple jurisdictions, including Orphan Drug Designations/Approvals.
• Delays in achievement of projected development goals.
• Management of additional regulatory burdens.
• Volatility in the market price for the Securities.
• Failure to protect and maintain intellectual property rights and third-party claims relating to misappropriation.
• Reliance on third parties to conduct and monitor pre-clinical studies and clinical trials.
• Product candidates being subject to controlled substance laws which may vary from jurisdiction to jurisdiction.
• Changes in laws, regulations, and guidelines relating to the business, including tax and accounting requirements.
• Reliance on early-stage research regarding the medical benefits, viability, safety, efficacy, and dosing of product candidates.
• Claims for personal injury or death arising from the use of future products and product candidates.
• Uncertainty relating to market acceptance of product candidates, if approved.
• Lack of experience in commercializing any products, including selling, marketing, or distributing pharmaceutical products.
• Securing third-party payor reimbursement for product candidates, if approved, and the level of pricing and reimbursement.
• Dependence on contract manufacturers and business disruptions affecting third-party suppliers and manufacturers.
• Lack of control in future production and selling prices of product candidates, if approved.
• Competition in the industry and inability to develop new technologies and products.
• Unfavorable publicity or consumer perception towards any products for which marketing authorization is received.
• Product liability claims and product recalls.
• Risks associated with expansion of business to other jurisdictions.
• Fraudulent activities of employees, contractors, and consultants.
• Reliance on key inputs and their related costs, and difficulty associated with forecasting demand for products.
• Operating risk and insurance coverage, and inability to manage growth.
• Conflicts of interest among officers and directors, and managing damage to reputation and third-party reputational risks.
• Relationships with customers and third-party payors and consequential exposure to applicable anti-kickback, fraud, and abuse and other healthcare laws.
• Exposure to information systems security threats.
• No dividends for the foreseeable future.
• Future sales of Common Shares by existing shareholders causing the market price for the Common Shares to fluctuate.
• Issuance of Common Shares in the future causing dilution to current shareholders.
• Events outside of the company's control could adversely affect operations.
• Ability to remediate any material weakness in internal control over financial reporting.
• Global geo-political events and government responses having a significant effect on the world economy.
• Failure to meet regulatory or ethical expectations on environmental impact, including climate change.
• Management discretion in applying the proceeds of any offerings, which may differ from stated intentions.
• As a foreign private issuer, the company is subject to different U.S. securities laws and rules, which may limit information publicly available to U.S. investors.
• Potential loss of foreign private issuer status in the future, which could result in significant additional costs and expenses.
• Reliance upon certain accommodations available as an emerging growth company, which may make Common Shares less attractive to some investors.
• Classification as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, which would subject U.S. investors to potentially significant adverse U.S. federal income tax consequences.

Future Outlook

The company plans to continue advancing its clinical development programs for CardiolRx in recurrent pericarditis and acute myocarditis, including the potential initiation of larger Phase III trials. It also intends to progress its novel subcutaneously administered drug formulation, CRD-38, into a clinical program. Proceeds from future offerings are expected to fund these business objectives, ongoing operations, working capital requirements, debt repayment, discretionary capital programs, and potential future acquisitions.

Management Comments

• Management believes that the assumptions underlying its forward-looking statements are reasonable, but acknowledges they may prove incorrect and cannot assure actual results will be consistent with these projections.
• The company currently possesses sufficient non-contingent financial resources to fund operations and capital requirements necessary to achieve its next significant milestones, including completing the Phase II MAvERIC-Pilot study, completing the Phase II ARCHER trial, and advancing CRD-38 into a clinical program.

Industry Context

Cardiol Therapeutics operates in the clinical-stage life sciences sector, specializing in anti-inflammatory and anti-fibrotic therapies for heart diseases. Its lead candidate, CardiolRx, targets rare and serious conditions like recurrent pericarditis and acute myocarditis, which currently lack FDA-approved treatments. The FDA's Orphan Drug Designation for pericarditis aligns with a broader industry trend to incentivize development for unmet medical needs in rare diseases. The company's development of CRD-38 for heart failure also positions it in a therapeutic area with significant healthcare costs and patient burden in developed nations.

Comparison to Industry Standards

• The U.S. Orphan Drug Designation program provides significant incentives, including seven-year marketing exclusivity and exemptions from certain FDA fees, for treatments affecting fewer than 200,000 people in the U.S.
• The program was successfully utilized to support the first FDA approval of another oral cannabidiol solution for the treatment of seizures associated with rare pediatric epilepsy syndromes, providing a precedent for CardiolRx's regulatory pathway.
• The European Commission's European Medicines Agency (EMA) has a similar orphan medicine product program for rare diseases, indicating a global recognition of the need for such incentives.
• Acute myocarditis affects an estimated 54,000 people in the U.S. per year, with average hospital charges per stay estimated at $110,000, highlighting a substantial unmet medical need and market opportunity.
• Heart failure, the target for CRD-38, is a leading cause of death and hospitalization in the developed world, with associated U.S. healthcare costs exceeding $30 billion annually, underscoring the large market potential for effective therapies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution from future offerings, but also potential for value appreciation from successful clinical development and commercialization. U.S. shareholders face potential adverse tax consequences due to the company's PFIC status.
• Investors: Opportunity to invest in a clinical-stage biotechnology company with promising early clinical data and regulatory advantages (Orphan Drug Designation), balanced against the high risks and costs inherent in drug development and the company's current financial profile.
• Patients: Potential for new and effective therapies for serious and rare heart conditions like recurrent pericarditis and acute myocarditis, as well as heart failure, addressing significant unmet medical needs.
• Employees: Continued employment and potential growth opportunities as the company advances its product pipeline, contingent on successful financing and clinical outcomes.
• Creditors: Potential for repayment of indebtedness from the proceeds of future securities offerings, enhancing the company's ability to manage its liabilities.

Next Steps

• Complete Phase II MAvERIC-Pilot study in recurrent pericarditis with CardiolRx (estimated H2 2024).
• Complete Phase II ARCHER trial in acute myocarditis with CardiolRx (estimated H1 2025).
• Advance the development of CRD-38 into a clinical program (estimated Q4 2024).
• Complete Phase 1 study with CRD-38 (estimated H2 2025).
• Potentially initiate a larger Phase III study in recurrent pericarditis with CardiolRx (timeframe TBD, estimated cost $20,000,000).
• Potentially initiate a Phase III ARCHER trial in acute myocarditis with CardiolRx (timeframe TBD, estimated cost $10,000,000).
• Potentially initiate a Phase II study with CRD-38 (timeframe TBD, estimated cost $10,000,000).
• Allocate funds to discovery research studies for new product candidates.
• Comply with applicable laws relating to drug manufacturing and distribution, including obtaining health regulatory approvals for commercialization.

Key Dates

Recommendation

The positive 8-week clinical data for CardiolRx in recurrent pericarditis and the FDA Orphan Drug Designation are significant de-risking events for a clinical-stage company, indicating strong progress and potential for future value. The shelf prospectus provides crucial financial flexibility for ongoing development. However, the company's history of losses, negative operating cash flow, and substantial accumulated deficit highlight ongoing financial challenges. The inherent high risks and costs associated with advancing drug candidates through later-stage clinical trials, coupled with the potential adverse U.S. tax implications of PFIC status, warrant a cautious 'Hold' recommendation. Investors should monitor further clinical trial results and the company's financial trajectory for clearer indications of long-term viability and commercial success.

Keywords

Cardiol Therapeutics, F-10, Shelf Prospectus, Securities Offering, Common Shares, Debt Securities, Warrants, Subscription Receipts, Units, Secondary Offering, Selling Securityholders, Clinical Trials, CardiolRx, Recurrent Pericarditis, Acute Myocarditis, MAvERIC-Pilot, ARCHER, Orphan Drug Designation, FDA, Cannabidiol, Heart Disease, Inflammation, Fibrosis, Life Sciences, Pharmaceutical, Biotechnology, Clinical Stage, Capital Raise, Dilution, PFIC